🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to researchers.

An International Challenge

Cases of gonorrhoea are on the rise around the world, with estimates suggesting more than 82 million instances per year. Particularly high rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the context of rising global incidence, the spread of superbugs and the very limited therapeutic options at this time.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, marketed under the name a brand name, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This medication, which is additionally indicated for urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This approval signifies a significant shift in the therapy of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Outcomes and Worldwide Availability

Based on data published in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which combines a dual-drug approach. The research enrolled hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Clinicians on the front lines have voiced hope. Access to a single-dose, oral treatment such as this is described as a "game-changer" for public health efforts. This is viewed as vital to reduce the burden of the illness for patients and to halt the transmission of untreatable gonorrhoea around the world.